Definitive Healthcare Corp. (NASDAQ:DH) Given Average Recommendation of “Hold” by Brokerages

Definitive Healthcare Corp. (NASDAQ:DH) has been assigned a consensus recommendation of “Hold” from the twelve ratings firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $5.35.

A number of research firms recently commented on DH. Barclays dropped their target price on Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating on the stock in a report on Monday, March 3rd. Stephens assumed coverage on Definitive Healthcare in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.00 target price for the company. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. Finally, The Goldman Sachs Group dropped their price target on shares of Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th.

Definitive Healthcare Stock Performance

Shares of NASDAQ DH opened at $2.59 on Friday. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. The firm’s 50-day moving average price is $4.38 and its two-hundred day moving average price is $4.39. The stock has a market capitalization of $292.44 million, a P/E ratio of -0.84, a P/E/G ratio of 4.06 and a beta of 1.51. Definitive Healthcare has a 52-week low of $2.55 and a 52-week high of $8.35.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The company had revenue of $62.29 million for the quarter, compared to analyst estimates of $60.60 million. As a group, sell-side analysts forecast that Definitive Healthcare will post 0.16 earnings per share for the current year.

Hedge Funds Weigh In On Definitive Healthcare

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DH. Irenic Capital Management LP increased its position in shares of Definitive Healthcare by 9.2% during the 4th quarter. Irenic Capital Management LP now owns 7,003,194 shares of the company’s stock worth $28,783,000 after purchasing an additional 590,009 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Definitive Healthcare by 36.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 6,053,233 shares of the company’s stock valued at $27,058,000 after purchasing an additional 1,626,813 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Definitive Healthcare by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,863,912 shares of the company’s stock valued at $7,661,000 after acquiring an additional 23,410 shares during the last quarter. State Street Corp increased its stake in shares of Definitive Healthcare by 29.4% in the third quarter. State Street Corp now owns 1,399,729 shares of the company’s stock valued at $6,257,000 after buying an additional 317,952 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Definitive Healthcare by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 1,272,660 shares of the company’s stock worth $5,231,000 after acquiring an additional 39,938 shares during the period. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.